That is interesting about Siegel and Spangler.
I suppose there is one thing to be said about people who support the nicotine inhalers but oppose e-cigarettes: one is made under tight QC and the other is a consumer product with few (if any) controls. It will be interesting to see what they say about e-cigarettes that achieve a pharmaceutical license, as one almost certainly will in 2012. Once one has done it, others will follow.
They will probably have to modify their spiel somewhat when e-cigs are routinely prescribed by doctors as an NRT. This will start in the UK, and then probably move to more EU countries. The US will be some time down the road because of the time and cost of obtaining the pharma license. However, the e-cig company (Intellicig UK) might well do some sort of a licensing deal with a US pharma company in order to progress the matter.
I think that it is better to have a vast number of consumers able to access the product, even if it is lacking in QC, rather than a very few able to obtain it on prescription. The end result will be a much greater reduction in harm. A proportion of those who obtain it on prescription will move up to the 2nd and 3rd-generation consumer models, in any case. There is some evidence that could be up to 92% of them.